Genmab A (GMAB) Free Cash Flow (2018 - 2026)
Genmab A's (GMAB) quarterly Free Cash Flow came in at $3.0 million in Q1 2026, down 98.95% YoY from $287.0 million in Q1 2025, and down 99.66% on a QoQ basis from $885.0 million in Q3 2025.
Genmab A (GMAB) Free Cash Flow (2018 - 2026) Analysis & Trends
Genmab A (GMAB) has 6 years of Free Cash Flow data on file, last reported at $3.0 million in Q1 2026.
- Quarterly Free Cash Flow fell 98.95% year-over-year to $3.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.2 billion (down 16.44% YoY) and the FY2025 annual result came in at -$6.0 billion, down 648.59% from the prior year.
- Free Cash Flow declined to $3.0 million in Q1 2026, from $885.0 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of $885.0 million in Q3 2025 to a low of $3.0 million in Q1 2026.
- A 3-year average of $412.6 million and a median of $327.0 million in 2025 frame the typical range for Free Cash Flow.
- Annual changes were most pronounced in 2025 — Free Cash Flow jumped 31.05% — and 2026, when it slumped 98.95%.
- Tracing GMAB's Free Cash Flow over 3 years: stood at $737.0 million in 2024, then grew by 20.08% to $885.0 million in 2025, then slumped by 99.66% to $3.0 million in 2026.
- The last three Free Cash Flow figures came in at $3.0 million (Q1 2026), $885.0 million (Q3 2025), and $327.0 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -389.61 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 437.80 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 477.44 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 292.04 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Genmab A | 2.05 Bn | 548.77 Mn | 1.07 Bn | 314.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 314.00 Mn |
| Jun 30, 2026 | 314.00 Mn |
| Mar 31, 2026 | 3.00 Mn |
| Mar 31, 2026 | 3.00 Mn |
| Sep 30, 2025 | 885.00 Mn |
| Sep 30, 2025 | 885.00 Mn |
| Jun 30, 2025 | 327.00 Mn |
| Jun 30, 2025 | 327.00 Mn |
| Mar 31, 2025 | 287.00 Mn |
| Mar 31, 2025 | 287.00 Mn |
| Sep 30, 2024 | 737.00 Mn |
| Sep 30, 2024 | 737.00 Mn |
| Jun 30, 2024 | 430.00 Mn |
| Jun 30, 2024 | 430.00 Mn |
| Mar 31, 2024 | 219.00 Mn |
| Mar 31, 2024 | 219.00 Mn |
| Sep 30, 2020 | 5,078.00 |
| Sep 30, 2020 | 5,078.00 |
| Dec 31, 2019 | 319.00 |
| Dec 31, 2019 | 319.00 |